Want to see TVGN full AI Analyst Report?
Top Page
Tevogen Bio Holdings
(NASDAQ:TVGN)
Select Model
Select Model
Rating:49Neutral
Price Target:
$7.00
▲(2.79% Upside)
Action:Reiterated
Date:08/27/26
The score is held down primarily by weak financial performance: no revenue, ongoing losses, continued cash burn, and negative equity that heightens financing/dilution risk. Technical signals are somewhat supportive in the near term (positive MACD; RSI not overbought; above 20/50 DMA) but longer-term trend damage persists (below 100/200 DMA). Valuation is difficult to support with a negative P/E tied to losses, while the corporate event is a modest governance positive with limited immediate financial impact.
Positive Factors
Reduced Debt Burden
The substantial reduction in debt improves the leverage profile and may reduce financing pressure relative to prior years. However, its benefit is constrained by negative equity, limited assets, and the company’s continuing need to fund operations externally.
Negative Factors
No Commercial Revenue
The absence of product revenue confirms that the business remains pre-commercial and dependent on research progress and future financing. Without a revenue base, operating costs cannot be funded internally, increasing execution risk before commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Reduced Debt Burden
The substantial reduction in debt improves the leverage profile and may reduce financing pressure relative to prior years. However, its benefit is constrained by negative equity, limited assets, and the company’s continuing need to fund operations externally.
Read all positive factors
Tevogen Bio Holdings (TVGN) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$43.63M
Dividend YieldN/A
Average Volume (3M)557.82K
Price to Earnings (P/E)―
Beta (1Y)1.19
Revenue GrowthN/A
EPS Growth36.06%
CountryUS
Employees18
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.83
Shares Outstanding6,511,540
10 Day Avg. Volume531,944
30 Day Avg. Volume557,817
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)-6.68
Price to Sales (P/S)0.00
P/FCF Ratio-4.44
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-10.14
Revenue Forecast (FY)N/A
Tevogen Bio Holdings Business Overview & Revenue Model
Company Description
Tevogen Bio Holdings Inc. is a clinical-stage biotechnology firm dedicated to developing "off-the-shelf" precision T cell therapies for conditions across virology, oncology, and neurology. Its flagship experimental product, TVGN 489, is a precisio...
Tevogen Bio Holdings Financial Statement Overview
Summary
Income Statement
10
Very Negative
Balance Sheet
12
Very Negative
Cash Flow
9
Very Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Mar 2024 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -204.98K | 0.00 | -403.58K | -378.36K | 0.00 | 0.00 |
| EBITDA | -20.95M | -25.57M | -13.14M | -58.89M | 4.64M | -14.99M |
| Net Income | -21.61M | -26.28M | -10.11M | -60.48M | 4.41M | -15.60M |
Balance Sheet | ||||||
| Total Assets | 4.73M | 4.38M | 3.46M | 5.51M | 7.74M | 7.66M |
| Cash, Cash Equivalents and Short-Term Investments | 1.08M | 552.37K | 1.28M | 1.05M | 5.48M | 7.12M |
| Total Debt | 3.04M | 3.10M | 2.89M | 95.42M | 40.01M | 23.48M |
| Total Liabilities | 13.62M | 12.62M | 10.14M | 99.93M | 41.69M | 24.15M |
| Stockholders Equity | -8.89M | -8.23M | -6.67M | -94.43M | -33.95M | -16.49M |
Cash Flow | ||||||
| Free Cash Flow | -11.63M | -12.39M | -12.00M | -8.30M | -9.13M | -5.38M |
| Operating Cash Flow | -11.57M | -12.33M | -12.00M | -8.17M | -8.66M | -5.27M |
| Investing Cash Flow | -64.44K | -64.44K | 0.00 | -133.00K | -479.04K | -109.73K |
| Financing Cash Flow | 12.03M | 11.66M | 12.23M | 3.87M | 7.50M | 12.50M |
Tevogen Bio Holdings Technical Analysis
Neutral
6.81
Price Trends
6.40
Positive
7.20
Negative
11.22
Negative
Market Momentum
0.14
Negative
53.66
Neutral
88.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TVGN, the sentiment is Neutral. The current price of 6.81 is above the 20-day moving average (MA) of 6.67, above the 50-day MA of 6.40, and below the 200-day MA of 11.22, indicating a neutral trend. The MACD of 0.14 indicates Negative momentum. The RSI at 53.66 is Neutral, neither overbought nor oversold. The STOCH value of 88.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for TVGN.
Tevogen Bio Holdings Risk Analysis
Tevogen Bio Holdings disclosed 76 risk factors in its most recent earnings report. Tevogen Bio Holdings reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tevogen Bio Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | $792.87M | -15.00 | -43.57% | ― | -66.63% | 57.89% | |
56 Neutral | $816.10M | -19.23 | -169.47% | ― | ― | -13.52% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | $43.63M | -1.16 | 248.50% | ― | ― | 36.06% | |
48 Neutral | $521.63M | -4.10 | -45.45% | ― | 2.33% | 36.86% | |
44 Neutral | $188.37M | -1.75 | -39.64% | ― | ― | -6.70% |
* Healthcare Sector Average
TVGN
Tevogen Bio Holdings
6.75
-38.38
-85.04%
NKTX
Nkarta
2.75
0.55
25.00%
CCCC
C4 Therapeutics
4.10
1.55
60.78%
STTK
Shattuck Labs
7.65
6.66
672.73%
NVCT
Nuvectis Pharma
25.19
18.66
285.76%
ACTU
Actuate Therapeutics, Inc.
1.69
-6.53
-79.44%
Tevogen Bio Holdings Corporate Events
Business Operations and StrategyExecutive/Board ChangesShareholder Meetings
Tevogen Bio Shareholders Approve Governance-Enhancing Charter Changes
Positive
Aug 26, 2026
As of July 23, 2026, Tevogen had 6,416,540 common shares outstanding, and on August 24, 2026, the company held its annual shareholders’ meeting, where a quorum was present and all proposals received strong support. Stockholders elected Dr. K...
Business Operations and StrategyRegulatory Filings and Compliance
Tevogen Bio Holdings Rebrands as Tevogen Inc.
Neutral
Jul 30, 2026
On July 29, 2026, Tevogen Bio Holdings Inc. filed a certificate of amendment to change its corporate name to Tevogen Inc., with the new name becoming effective on July 30, 2026. In tandem, the board approved a related bylaws amendment to reflect t...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.